Clinical trial · Interventional
A Study of Prexasertib (LY2606368) in Japanese Participants With Advanced Cancers
A Phase 1 Study of LY2606368 in Japanese Patients With Advanced Solid Tumors
NCT02514603CI-TRIAL-00027722completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The primary purpose of this study is to assess the tolerability of prexasertib in Japanese participants with advanced solid cancers.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neoplasm | Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Prexasertib | Drug | Prexasertib | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Prexasertib
- description
- Prexasertib intravenously (IV) on day 1 of a 14 day cycle. Treatment with prexasertib may continue until disease progression, unacceptable toxicity, or other discontinuation criteria are met.
- interventionNames
- Drug: Prexasertib
Primary outcomes (1)
- measure
- Number of Participants with Prexasertib Dose-Limiting Toxicities (DLT)
- timeFrame
- Cycle 1 (14 day cycle)
Secondary outcomes (3)
- measure
- Pharmacokinetics (PK): Maximum Concentration (Cmax) of Prexasertib
- timeFrame
- Pre-dose up to 7 Days Post Treatment in Cycle 1/2 (Approximately 7 Days)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
Show eligibility criteria text
Inclusion Criteria: * Participant must be appropriate candidate for experimental therapy, as determined by investigator, after available standard therapies have failed * Participant must have diagnosis of cancer that is advanced or metastatic * Participant must have discontinued previous treatments for cancer and recovered from the acute effects of that therapy * If participant is of reproductive potential, must agree to use medically approved contraceptive precautions during the study and for three months following the last dose of study drug * If the participant is a female of childbearing potential, must have had a negative serum or urine pregnancy test within 7 days of the first dose of study drug and must not be breast feeding Exclusion Criteria: * Participant must not have symptomatic central nervous system malignancy or metastasis * Participant must not have current hematologic malignancy * Participant must not have an active symptomatic fungal, bacterial or viral infection, including human immunodeficiency virus (HIV) or Hepatitis A, B, or C * Participant must not have a serious cardiac condition
References
Publications (0)
Data not yet available
No reference posted for this study.